Robert W. Baird Has Lowered Expectations for Certara (NASDAQ:CERT) Stock Price

Certara (NASDAQ:CERT) had its target price reduced by research analysts at Robert W. Baird from $18.00 to $13.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Robert W. Baird’s price target indicates a potential upside of 19.16% from the company’s previous close.

Other analysts also recently issued reports about the stock. KeyCorp decreased their target price on shares of Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Barclays decreased their target price on shares of Certara from $16.00 to $14.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 15th. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Friday, September 27th. Finally, JMP Securities reissued a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $16.25.

Certara Stock Performance

Shares of NASDAQ CERT opened at $10.91 on Tuesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. Certara has a one year low of $9.99 and a one year high of $19.87. The business’s 50-day moving average price is $11.10 and its two-hundred day moving average price is $13.77. The company has a market capitalization of $1.76 billion, a P/E ratio of -21.82, a price-to-earnings-growth ratio of 4.88 and a beta of 1.51.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.10 EPS. Analysts anticipate that Certara will post 0.27 earnings per share for the current fiscal year.

Insider Activity at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the transaction, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Certara news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.39% of the company’s stock.

Institutional Investors Weigh In On Certara

Several institutional investors and hedge funds have recently bought and sold shares of CERT. Sei Investments Co. grew its holdings in shares of Certara by 12.4% in the 1st quarter. Sei Investments Co. now owns 715,514 shares of the company’s stock worth $12,793,000 after purchasing an additional 79,013 shares during the last quarter. Geneva Capital Management LLC grew its holdings in shares of Certara by 15.1% in the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock worth $78,747,000 after purchasing an additional 579,349 shares during the last quarter. Motley Fool Asset Management LLC grew its holdings in shares of Certara by 94.0% in the 1st quarter. Motley Fool Asset Management LLC now owns 96,792 shares of the company’s stock worth $1,731,000 after purchasing an additional 46,897 shares during the last quarter. Silvercrest Asset Management Group LLC grew its holdings in shares of Certara by 27.3% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 516,300 shares of the company’s stock worth $9,231,000 after purchasing an additional 110,636 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of Certara in the 1st quarter worth about $571,000. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.